Health & Biotech
Weed Week: The lazy stoner stereotype is a myth and this Aussie uni wants to study home grown cannabis
Health & Biotech
ASX Health Stocks: Invion surges 17pc after saying its lead drug can kill anal cancer
Health & Biotech
Wellnex Life opens SPP with record Q1 FY23 sales forecast
Health & Biotech
ASX Health Stocks: Biotron expands COVID-19 study in Thailand; Noxopharm, Clarity progress pancreatic cancer research
Health & Biotech
Kazia Therapeutics lays groundwork for a possible launch in the US
Health & Biotech
ASX Health Stocks: Antisense commences trial dosing, Shine lawyers deliver historic $300m settlement
Health & Biotech
When you’re smilin’ – Wellnex to acquire premium teeth whitening brand Mr. Bright
Health & Biotech
HealthKick Podcast: PTX partners with the US’s largest cancer centre on personalised treatment
Health & Biotech
Australia’s biotech industry is thriving, with ASX-listed companies up 19% since 2019
Health & Biotech
ASX Health Stocks: Radiopharm wins US FDA Orphan status, set to accelerate treatment for rare bone cancer in kids
Health & Biotech
Prescient joins up with renowned US cancer centre in fight against blood cancer
Health & Biotech
ASX Health Stocks: Invion proves photodynamic therapy is effective against the Zika virus
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.